Nature Communications · Apr 2026
Nature Communications paper describing a deep-learning and yeast-screening approach that independently converged on azole compounds for Leigh syndrome, consistent with Perlara’s SURF1-related work.
Perlara: building the YC for rare disease parents
Company research
Public company, workplace, funding, and market signals
Overview
Perlara is a Bay Area rare-disease biotech and Public Benefit Corporation focused on inherited metabolic diseases. It operates a yeast-first, patient-partnered drug discovery platform (REMIT) that screens repurposable compounds, validates hits in patient cells, and advances programs into IND-enabling work and clinical studies. Public funding data is inconsistent across third-party sources; the best current public estimate I found is about $17M raised, with the company also reporting a $1.7M SBIR award in 2025.
Primary product
REMIT, a yeast-first inherited-metabolic-disease drug discovery and development platform
Founded
2014
Headquarters
South San Francisco, California, United States
Team size
10-20
Work style
Remote
Industry
Biotechnology Research
Sub-industry
Open Positions
0 jobs at Perlara
No open positions
Check back later for new openings